The MiR-142 Suppresses U-87 Glioblastoma Cell Growth by Targeting EGFR Oncogenic Signaling Pathway
Overview
Authors
Affiliations
Glioblastoma is the most lethal malignancy of the brain and is resistant to conventional cancer treatments. Gene-therapy approaches like using tumor suppressor miRNAs are promising in the treatment of glioblastoma. They control the expression of oncogenes and influence tumor features and behaviors. Therefore, in the present study, it was predicted that miR-142 regulates oncogenic epidermal growth factor receptor () signaling pathway via TargetScan and miRWalk online tools. Its differential expression level was reduced in glioblastoma according to the previous microarray results, and its predicted target genes were upregulated, as shown by the Expression Atlas. The miR-142 was overexpressed in U-87 glioblastoma cells via lentiviral transduction, and the way it influences proliferation and migration of cells was investigated through MTT assay and wound healing assay. Apoptosis rate was also measured via the Annexin V assay, and cell-cycle analysis was done. Then, real-time polymerase chain reaction (real-time PCR) and western blotting were performed to assess fold changes in mRNA and protein levels of the miR-142 predicted targets. Direct target genes of miR-142 were confirmed through a dual-luciferase reporter assay. The miR-142 significantly suppressed cell proliferation and migration and induced apoptosis and cell-cycle arrest in U-87 glioblastoma cells. This was accompanied by a decrease in expression of SHC adaptor protein 4 (), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (), v-akt murine thymoma viral oncogene homolog 1 (), Kirsten rat sarcoma viral oncogene homolog (), and mitogen-activated protein kinase 8 () oncogenes at mRNA and protein levels in glioblastoma cells. Also, was demonstrated as a direct target of miR-142. Overall, miR-424 acts as tumor suppressor miRNA in glioblastoma cells.
Advances on the therapeutic potential of cell receptor activation in glioblastoma.
Contreras-Chavez G, Zapi-Colin L, Contreras I, Estrada J Mol Biol Rep. 2025; 52(1):207.
PMID: 39907852 DOI: 10.1007/s11033-025-10312-w.
Lei W, Yiming S, Qiang P, Xin C, Peng G, Baofeng Z Mol Neurobiol. 2024; 62(2):1433-1450.
PMID: 38995443 DOI: 10.1007/s12035-024-04342-x.
Ahmadnia A, Mohammadi S, Yamchi A, Kalani M, Farazmandfar T, Khosravi A Curr Issues Mol Biol. 2024; 46(4):2931-2945.
PMID: 38666913 PMC: 11048765. DOI: 10.3390/cimb46040183.
High yield killing of lymphoma cells by anti-CD22 CAR-NK cell therapy.
Abbaszade Dibavar M, Soleimani M, Mohammadi M, Soufi Zomorrod M In Vitro Cell Dev Biol Anim. 2024; 60(4):321-332.
PMID: 38589736 DOI: 10.1007/s11626-024-00895-2.
Use of microRNAs as Diagnostic, Prognostic, and Therapeutic Tools for Glioblastoma.
Valle-Garcia D, la Cruz V, Flores I, Salazar A, Pineda B, Meza-Sosa K Int J Mol Sci. 2024; 25(5).
PMID: 38473710 PMC: 10931459. DOI: 10.3390/ijms25052464.